What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?

• Nicola Silvestris

Affiliations

Nicola Silvestris

Medical Oncology Unit, IRCCS Istituto Tumori ''Giovanni Paolo II'' of Bari, 70124 Bari, Italy; Department of Biomedical Sciences and Human Oncology, University of Bari ''Aldo Moro'', 70124 Bari, Italy; Correspondence author.